July 31, 2014
Below are current clinical trials.7 studies in Irritable bowel syndrome
(open studies only).
Filter this list of studies by location, status and more.
Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals with Campylobacter infection are also known to develop chronic bowel problems such as Irritable Bowel Syndrome (IBS). The researchers are doing this study to understand if changes in gut bacteria and gut mucosal lining during an acute infection can help identify individuals who might be at risk for developing problems in the future.
The purpose of this study is to develop a resource (bank) of biospecimens and data collected from individuals with functional gastrointestinal disorders (FGID) to facilitate discovery and development of novel microbial biomarkers of disease and response to treatment, and novel targeted therapeutic strategies for FGID.
To better understand the relationship between gut barrier function and the symptomatology and pathophysiology of IBS.
Some people develop chronic abdominal pain with diarrhea or constipation after an episode of acute bacterial gastroenteritis. These symptoms can be consistent with post-infectious irritable bowel syndrome (IBS) and can last long after the acute infection is over. The exact reason why certain individuals develop these symptoms whereas others don't is not exactly clear. The researchers are studying changes in gastrointestinal permeability (movement of contents across the lining of the intestine) and transit (movement of food through the gastrointestinal tract). The researchers are also studying if there are any genetic risk factors that are associated with development of this disorder.
This study comprises three sub-studies. The objective of sub-study 1 is to characterize the dose-response, efficacy, and safety of ABT-494 compared to placebo in inducing clinical remission in order to identify the induction dose of ABT-494 for further evaluation in sub-study 2. The objective of sub-study 2 is to evaluate the efficacy and safety of ABT-494 compared to placebo in inducing clinical remission in participants. The objective of sub-study 3 is to evaluate the efficacy and safety of ABT-494 compared to placebo in achieving clinical remission in participants who had a response following induction with ABT-494.
The purpose of this study is to measure 48 hour fecal bile acids in IBS-D adolescents and compare it to HC; measure serum C4 and FGF-19 in adolescents with IBS-D and HC and compare it to 48 hour fecal bile acid loss; measure primary bile acids concentration in 48 hour stool collection in adolescents with IBS-D and compare it to HC.
This study will evaluate obesity as a comorbidity in a population of patients with irritable bowel syndrome (IBS), and assess this cohort for vitamin D-deficiency. It will also determine whether alterations in the fecal microbiome and metaproteome, associated with vitamin D deficiency or other factors, underpin obesity-IBS comorbidity.
- Irritable bowel syndrome. The National Digestive Diseases Information Clearinghouse. http://www.digestive.niddk.nih.gov/ddiseases/pubs/ibs/. Accessed April 23, 2014.
- Camilleri M. Peripheral mechanisms in irritable bowel syndrome. New England Journal of Medicine. 2012;367:1626.
- Ferri FF. Ferri's Clinical Advisor 2014: 5 Books in 1. Philadelphia, Pa.: Mosby Elsevier; 2014. https://www.clinicalkey.com. Accessed April 23, 2014.
- Wald A. Diagnosis of irritable bowel syndrome. http://www.uptodate.com/home. Accessed April 23, 2014.
- Wald A. Pathophysiology of irritable bowel syndrome. http://www.uptodate.com/home. Accessed April 23, 2014.
- Wald A. Treatment of irritable bowel syndrome. http://www.uptodate.com/home. Accessed April 23, 2014.
- Rome III diagnostic criteria for functional gastrointestinal disorders. Rome Foundation. http://www.romecriteria.org/criteria/. Accessed April 23, 2014.
- Cristofori F, et al. Increased prevalence of celiac disease among pediatric patients with irritable bowel syndrome: A 6-year prospective cohort study. Journal of the American Medical Association Pediatrics. In press. Accessed May 5, 2014.
- Brandt LJ, et al. An evidence-based systematic review on the management of irritable bowel syndrome. American Journal of Gastroenterology. 2009;104(suppl):1.
- AskMayoExpert. IBS. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2014.
- Lakhan SE, et al. Mindfulness-based therapies in the treatment of somatization disorders: A systematic review and meta-analysis. PLoS One. 2013;8:e71834.
- Muir JG, et al.The low FODMAP diet for treatment of irritable bowel syndrome and other gastrointestinal disorders. Gastroenterology & Hepatology. 2013;9:450.
- Vazquez-Roque MI, et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: Effects on bowel frequency and intestinal function. Gastroenterology. 2013;144:903.
- Hungin APS, et al. Systematic review: Probiotics in the management of lower gastrointestinal symptoms in clinical practice — an evidence-based international guide. Alimentary Pharmacology and Therapeutics. 2013;38:864.
- Relaxation techniques for health: An introduction. National Center for Complementary and Alternative Medicine. http://nccam.nih.gov/health/stress/relaxation.htm. Accessed May 6, 2014.
- Herbs at a glance: Peppermint oil. National Center for Complementary and Alternative Medicine. http://nccam.nih.gov/health/peppermintoil. Accessed May 6, 2014.
- Manheimer E, et al. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database of Systematic Reviews. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005111.pub3/abstract. Accessed May 18, 2014.
- Lindfors P, et al. Effects of gut-directed hypnotherapy on IBS in different clinical settings — results from two randomized, controlled trials. American Journal of Gastroenterology. 2012;107:276.
- McKenzie YA, et al. British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults. Journal of Human Nutrition and Dietetics. 2012:25;260.
- Chao G, et al. Effectiveness of acupuncture to treat irritable bowel syndrome: A meta-analysis. World Journal of Gastroenterology. 2014;20:1871.
- Rey E, et al. Chronic constipation, irritable bowel syndrome with constipation and constipation with pain/discomfort: Similarities and differences. American Journal of Gastroenterology. In press. Accessed March 4, 2014.
- Camilleri M. Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome. Expert Opinion on Pharmacotherapy. 2013;14:1151.
- Golden AK. Decision Support System. Mayo Clinic, Rochester, Minn. April 24, 2014.
- U.S. News best hospitals 2013-2014. U.S. News & World Report. http://health.usnews.com/best-hospitals/rankings/gastroenterology-and-gi-surgery. Accessed April 24, 2014.
- Picco MF (expert opinion). Mayo Clinic, Jacksonville, Fla. May 14, 2014.
- Ottillinger B, et al. STW 5 (Iberogast) — A safe and effective standard in the treatment of functional gastrointestinal disorders. Wiener Medizinische Wochenschrift. 2013;163:65.
- Dai C, et al. Probiotics and irritable bowel syndrome. World Journal of Gastroenterology. 2013;19:5973.
- Sisson G, et al. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome — a 12 week double-blind study. Alimentary Pharmacology and Therapeutics. In press. Accessed May 18, 2014.
- Bauer BA (expert opinion). May Clinic, Rochester, Minn. May 16, 2014.